Printer Friendly Version 

2015 Press Releases

Keyword Search
 
2015 | 2014 | 2013 | 2012
DateTitle 
05/04/15Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis
--Bayer to develop ISIS-FXI Rx broadly for the prevention of thrombosis-- --Transaction maximizes value of the ISIS-FXI Rx program-- --Partnership provides Isis with significant potential to participate in commercial success of ISIS-FXI Rx-- CARLSBAD, Calif., May 4, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) has entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention of thrombo... 
Printer Friendly Version
04/30/15Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen
CARLSBAD, Calif., April 30, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed target to treat a neurological disorder.  This is the ninth program to advance, which includes four drugs in development, under Isis' and Biogen's broad strategic alliance to discover and develop novel therapies to treat neurological and neuromuscular disorders.  "Together with B... 
Printer Friendly Version
04/29/15Webcast Alert: Isis Pharmaceuticals' First Quarter 2015 Financial Results Conference Call
CARLSBAD, Calif., April 29, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' First Quarter 2015 Financial Results When: Tuesday, May 5 at 11:30 a.m. ET / 8:30 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our website listed above. ... 
Printer Friendly Version
04/22/15Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis
Up to 92 percent reduction in transthyretin protein in patients with familial amyloid polyneuropathy CARLSBAD, Calif., April 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive data from an ongoing open-label extension (OLE) study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).  FAP patients completing the ongoing Phase 3 study are eligible to enroll in this OLE study in which all patients receive ISIS-TTRRx.  An analysis conducted... 
Printer Friendly Version
04/10/15Isis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., April 10, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 in New York, NY; 40th Annual Deutsche Bank Health Care Conference on Thursday, May 7, 2015 in Boston, MA; 2015 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 12, 201... 
Printer Friendly Version
03/23/15Isis Pharmaceuticals Reports Positive Phase 1 Data on Isis-ANGPTL3Rx
CARLSBAD, Calif., March 23, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx.  In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93 percent with a mean reduction of up to 84 percent from baseline (p<0.001).  In addition, statistically significant reductions from baseline in lipid parameters w... 
Printer Friendly Version
03/06/15Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
CARLSBAD, Calif., March 6, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $9 million milestone payment from Biogen Idec related to advancing the ongoing pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA).  ENDEAR, a Phase 3 study of ISIS-SMNRx, is a randomized, double-blind, sham-procedure controlled thirteen month study in approximately 110 infants diagnosed with SMA.  The study will evaluate the e... 
Printer Friendly Version
03/02/15Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx
CARLSBAD, Calif., March 2, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $15 million milestone payment from GSK related to advancing the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).  "We are very pleased with the progress we are making with ISIS-TTRRx, and plan to report data from the Phase 2/3 study in 2017.  We have many patients who have completed the fifteen months of dosing and are now recei... 
Printer Friendly Version
02/27/15Isis Reports Financial Results and Highlights for 2014
- Isis Outperforms 2014 Projections for Pro Forma Net Operating Loss and Year-end Cash - Isis Achieves Profitable Fourth Quarter - More than $230 Million in Payments from Partners Drives Significantly Improved Financial Results - Conference Call Webcast Friday, February 27, 10:30 a.m. ET at www.isispharm.com CARLSBAD, Calif., Feb. 27, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced it significantly outperformed both its pro forma net operating loss (NOL... 
Printer Friendly Version
02/24/15ISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels
CARLSBAD, Calif., Feb. 24, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-PKKRx.  In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).  HAE is a severe and rare genetic disease that is ... 
Printer Friendly Version
02/20/15Webcast Alert: Isis Pharmaceuticals' 2014 Financial Results and Highlights Conference Call
CARLSBAD, Calif., Feb. 20, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What:        Isis Pharmaceuticals' 2014 Financial Results and Highlights Conference Call When:    Friday, February 27 at 10:30 a.m. ET / 7:30 a.m. PT Where:     www.isispharm.com How:       Live on the Internet.  Simply log onto our website... 
Printer Friendly Version
02/10/15Isis Pharmaceuticals Earns $5 Million Milestone Payment From Biogen Idec
CARLSBAD, Calif., Feb. 10, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $5 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder under its broad strategic collaboration with Biogen Idec to develop drugs to treat patients with neurological disorders.  Isis will continue to evaluate the target with the goal of advancing this program into development.  "Together with... 
Printer Friendly Version
02/05/15Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancing New Drug Into Development to Treat a Neurodegenerative Disease
--Fourth Drug to Enter Development Under Broad Strategic Collaboration CARLSBAD, Calif., Feb. 5, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec for initiating the investigational new drug (IND)-supporting studies of ISIS-BIIB4Rx.  ISIS-BIIB4Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.  ISIS-BIIB4Rx is the fourt... 
Printer Friendly Version
02/04/15Isis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 4, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at: 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015 in New York, NY; Cowen and Company 35th Annual Health Care Conference on Wednesday, March 4, 2015 in Boston, MA; and 27th Annual ROTH Conference on Monday, March 9, 2015 in Laguna Niguel. The above listed dates are s... 
Printer Friendly Version
02/03/15Isis Pharmaceuticals Reports Data From Phase 2 Study of ISIS-PTP1B Rx in Patients With Type 2 Diabetes
CARLSBAD, Calif., Feb. 3, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today top-line results from a Phase 2 study of ISIS-PTP1BRx in patients with type 2 diabetes.  In the Phase 2 study patients treated with ISIS-PTP1BRx achieved statistically significant reductions in body weight and hemoglobin A1c (HbA1c).  In patients treated with ISIS-PTP1BRx, a mean reduction in HbA1c of 0.7 percentage points from baseline was achieved at 36 weeks, compared to a mean reduction o... 
Printer Friendly Version
01/14/15Isis Pharmaceuticals Earns $7M for Advancing ISIS-SMN Rx in Children With Spinal Muscular Atrophy
CARLSBAD, Calif., Jan. 14, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).  The open-label extension study of ISIS-SMNRx is offered to those children with SMA who have completed dosing in Isis' previous studies.  In this study, children with SMA are receiving a 12 ... 
Printer Friendly Version
01/09/15Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA Therapeutics
New Agreement Includes Cross-License on Four Disease Targets, Providing Each Company Exclusive RNA Therapeutic License Rights for Two Programs CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2015-- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), leaders in RNA-targeted therapeutics, announced today they have formed a new agreement, extending their existing strategic partnership – formed originally in ... 
Printer Friendly Version
01/08/15Isis Pharmaceuticals Significantly Improves Upon 2014 Financial Guidance
Strong Performance represents success of novel business strategy CARLSBAD, Calif., Jan. 8, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Company expects to significantly improve upon its 2014 financial guidance.  The Company expects to end 2014 with a pro forma net operating loss (NOL) in the mid to high teens and more than $725 million in cash.  The significantly improved financial performance of the Company in 2014 was a result of the successful exe... 
Printer Friendly Version
01/06/15Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics
Isis-owned Subsidiary Launched to Conduct Development and Commercialization of Isis' Lipid Franchise Drugs CARLSBAD, Calif. and CAMBRIDGE, Mass., Jan. 6, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the appointment of Paula Soteropoulos as president and chief executive officer (CEO) of Akcea Therapeutics, the Isis-owned, lipid franchise subsidiary responsible for the development and commercialization of Isis' lipid drugs, ISIS-APOCIIIRx, ISIS-APO(a)Rx, ISIS-A... 
Printer Friendly Version
01/05/15Isis Pharmaceuticals Appoints Sarah Boyce As Chief Business Officer
Isis Strengthens Management Team Adding Strategic Business and Strategic Marketing Expertise CARLSBAD, Calif., Jan. 5, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that Sarah Boyce has joined the company as chief business officer.  In this newly created position, Ms. Boyce will provide strategic leadership from a commercial background and lead Isis' corporate development activities, including corporate communications, business development, patient advocacy, c... 
Printer Friendly Version
01/05/15Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract
-- Collaboration Combines Isis' RNA-Targeted Technology With Expertise of Janssen in Autoimmune Disorders and Therapeutic Formulation -- CARLSBAD, Calif., Jan. 5, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has entered into a global collaboration with Janssen Biotech, Inc. (Janssen) to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract.  The collaboration brings together Isis' RNA-targeted t... 
Printer Friendly Version
01/02/15Isis Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif., Jan. 2, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 2:30 p.m. PT in San Francisco, CA. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis w... 
Printer Friendly Version

Online Investor Kit

Quickly download files right from our Investor Relations Web site.

Learn More

Financial Tearsheet

Download a brief overview of Isis.

Learn More

News Feeds

Get the latest.

Subscribe

Receive Isis alerts in your email.

Sign Up